Waldencast agrees to sell Obagi Medical for up to $460 million

Waldencast agreed to sell Obagi Medical to Bridgepoint for up to $460 million, a major divestiture that should help the company repay about $178 million of senior term debt at closing. The transaction is expected to close in Q3 2026 and is not subject to financing or shareholder approval. The article also notes mixed operating performance, with $272 million of revenue, negative EBITDA of $5.78 million, and Canaccord cutting its price target to $2.00 from $4.00 after a $72 million sales print.

Analysis

This is less a simple asset sale than a balance-sheet reset that shifts WALD from a highly leveraged, two-brand roll-up to a cleaner, narrower equity story. The first-order upside is obvious deleveraging, but the more interesting second-order effect is that management is effectively conceding Obagi was the monetizable asset while preserving optionality around Milk Makeup; that usually improves survivability but not necessarily equity duration unless the remaining business can compound on its own. In other words, the market may re-rate the structure before it re-rates the earnings power.

The key trading issue is that the announced enterprise value looks much larger than the current equity value, but that headline is probably overstating what accrues to holders after debt, transaction adjustments, and working-capital true-ups. The equity can still work if the closing path is clean and the loan repayment meaningfully reduces distress risk, yet the bear case is that cash burns in the remaining business and the market treats the divestiture as a liquidation of the best asset rather than a transformation. That would leave the stock as a stranded consumer-brand stub with poor multiple support.

The contrarian angle is that consensus may be underestimating how quickly a cleaner balance sheet can change financing terms and strategic flexibility over the next 2-4 quarters. If management uses the proceeds to eliminate creditor overhang and stabilize Milk Makeup, even a modest EV/EBITDA multiple on a smaller revenue base can create more upside than the pre-deal conglomerate structure. The main reversal risk is execution: any delay in closing, weaker-than-expected net proceeds, or continued operating losses at the stub could quickly pull the stock back toward liquidation value rather than growth value.

Key Decisions for Investors

• Long WALD common only as a special-situation trade into close: size small, hold 3-9 months, targeting a re-rating on deleveraging and reduced bankruptcy discount; exit if the deal slips or cash proceeds disappoint.
• Buy WALD Jan-2027 out-of-the-money calls for convexity around closing; risk/reward is favorable if the market starts valuing the remaining Milk Makeup business on a normalized multiple, but premium should be treated as event-risk capital.
• Pair trade: long WALD / short a basket of weakly profitable small-cap consumer brand roll-ups with similar leverage profiles over the next 6-12 months; thesis is that cleaner balance sheets should outperform as funding conditions remain selective.
• Avoid chasing AMZN on the Obagi online channel angle; the Amazon distribution win is more likely to help category visibility than create meaningful near-term earnings impact, so any sympathy move should be sold into strength.
• If WALD rallies into closing on headline EV, consider trimming into strength; the risk/reward worsens once the market prices the gross transaction value instead of the residual equity claim after debt and restructuring friction.